With hospitals in Chelsea and Sutton, and a chemotherapy suite at Kingston Hospital, The Royal Marsden treats 50,000 patients from across the UK and abroad every year. Many of these patients benefit from tailored treatment programmes accomplished through provision of molecular diagnostics – allowing doctors to determine which specific treatments will be of most benefit to a particular patient.
The ICR and The Royal Marsden are internationally renowned for our work together to conduct early- and late-phase clinical trials. Our joint Drug Development Unit, which sees around 300 patients per year, is one of the largest centres for phase I trials in the world and makes an important contribution to the worldwide effort to discover and develop new cancer drugs.
The ICR and The Royal Marsden together are ranked in the top four centres for cancer research and treatment worldwide. In 2006, we were selected as a National Institute for Health Research Biomedical Research Centre specialising in cancer.